Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579403 | 0.84 | USP7 (0.49) | USP7MEN1NPC1RAB9AKMT2A | |
| SCHEMBL7256621 | 0.79 | HPGDS (0.49) | USP7MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3230297 | 0.78 | USP7 (0.49) | USP7 | |
| SCHEMBL27571466 | 0.77 | USP7 (0.54) | USP7MEN1NPC1RAB9AKMT2A | |
| SCHEMBL27573376 | 0.77 | MAP4K4 (0.43) | USP7MEN1NPC1RAB9AKMT2A | |
| SCHEMBL15089131 | 0.75 | MAP4K4 (0.47) | USP7MEN1NPC1RAB9AKMT2A | |
| SCHEMBL29360194 | 0.73 | GSK3B (0.46) | USP7MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4647645 | 0.73 | GSK3B (0.46) | USP7MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4905628 | 0.73 | ADORA2A (0.56) | MEN1KMT2ALMNAADORA2AADORA1 | |
| SCHEMBL29115860 | 0.72 | MAPK1 (0.53) | MEN1KMT2ALMNAADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745020-B2 | Metallic compound and organic electroluminescence device comprising the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-06-29 | — | — | US | disclosed |
| US-20080193795-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193795-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | PRMT5, CHRM5, PRMT6 | USP7 3612/4885MEN1 768/4885NPC1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.